In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 microg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.
Illnait-Zaragozi
Maria-Teresa
MT
Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, PO Box 9015, 6500 GS Nijmegen, The Netherlands.
Martínez
Gerardo F
GF
Curfs-Breuker
Ilse
I
Fernández
Carlos M
CM
Boekhout
Teun
T
Meis
Jacques F
JF
D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology; D003453:Cryptococcosis / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D003462:Cuba; D006801:Humans; D008826:Microbial Sensitivity Tests; D009570:Nitriles / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
D000935:Antifungal Agents; D001393:Azoles; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole